ReviewCancers2022
Ovarian Adnexal Reporting Data System (O-RADS) for Classifying Adnexal Masses: A Systematic Review and Meta-Analysis.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- GI-RADS versus O-RADS in the differential diagnosis of adnexal masses: a systematic review and head-to-head meta-analysis.Ultrasonography (Seoul, Korea) · 2024Pooled it
- Comparative Diagnostic Performance of IOTA Simple Rules, O-RADS US, and Subjective Assessment in Differentiating Benign from Malignant Adnexal Masses.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026Article
- O-RADS for assessment of adnexal lesions: current status, challenges and future directions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors.Molecular and clinical oncology · 2026Article
- Giant mucinous ovarian cystadenoma mimicking malignancy: a case report and review of diagnostic challenges.Journal of surgical case reports · 2026Article
- Diagnostic performance of deep learning models on ultrasound images for distinguishing benign from malignant ovarian cysts.Journal of ovarian research · 2026Article
- Paratubal Leiomyoma Mimicking Ovarian Malignancy: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- The Quantification Paradox in Gynecologic Color Doppler Ultrasound: From Spectral Indices to Microvascular Imaging and Artificial Intelligence.International journal of women's health · 2026Review
- Diagnostic accuracy of artificial intelligence in detection of ovarian cancer-a pilot study.Frontiers in medicine · 2026Article
- Diagnostic performance and interobserver agreement of O-RADS US v2022 and its combination with serum biomarkers in surgically treated epithelial ovarian-adnexal masses.Frontiers in medicine · 2026Article
- A Case Report of Malignant Struma Ovarii With Papillary Thyroid Carcinoma.Clinical case reports · 2025Article
- OTC-NET: A Multimodal Method for Accurate Diagnosis of Ovarian Cancer in O-RADS Category 4 Masses.Cancers · 2025Article
- Can transabdominal shear wave elastography play a role in solving the dilemma of complex cystic and solid ovarian tumors by ultrasound?Journal of ultrasound · 2025Article
- Accurate prediction of benign and malignant adnexal tumors in surgical resection and conservative treatment: construction and external validation of a diagnostic model based on CEUS, HE4, and O-RADS US v2022 evaluation.Journal of ovarian research · 2025Article
- A nomogram combining clinical features, O-RADS US, and radiomics based on ultrasound imaging for diagnosing ovarian cancer.Scientific reports · 2025Article
- Review
- Ovarian-Adnexal Imaging-Reporting and Data System (O-RADS) ultrasound version 2019: a prospective validation and comparison to updated version (v2022) in pathologically confirmed adnexal masses.European radiology · 2025Article
- Automatic segmentation model and machine learning model grounded in ultrasound radiomics for distinguishing between low malignant risk and intermediate-high malignant risk of adnexal masses.Insights into imaging · 2025Article
- Efficacy of a combination of O-RADS, CEUS, and CA125, in identification of ovary-adnexal malignant lesions.American journal of cancer research · 2025Article
- Updates on Imaging of Common Urogenital Neoplasms.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this systematic review and meta-analysis, we aimed to assess the pooled diagnostic performance of the so-called Ovarian Adnexal Report Data System (O-RADS) for classifying adnexal masses using transvaginal ultrasound, a classification system that was introduced in 2020. We performed a search for studies reporting the use of the O-RADS system for classifying adnexal masses from January 2020 to April 2022 in several databases (Medline (PubMed), Google Scholar, Scopus, Cochrane, and Web of Science). We selected prospective and retrospective cohort studies using the O-RADS system for classifying adnexal masses with histologic diagnosis or conservative management demonstrating spontaneous resolution or persistence in cases of benign appearing masses after follow-up scan as the reference standard. We excluded studies not related to the topic under review, studies not addressing O-RADS classification, studies addressing MRI O-RADS classification, letters to the editor, commentaries, narrative reviews, consensus documents, and studies where data were not available for constructing a 2 × 2 table. The pooled sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio (DOR) were calculated. The quality of the studies was evaluated using QUADAS-2. A total of 502 citations were identified. Ultimately, 11 studies comprising 4634 masses were included. The mean prevalence of ovarian malignancy was 32%. The risk of bias was high in eight studies for the "patient selection" domain. The risk of bias was low for the "index test" and "reference test" domains for all studies. Overall, the pooled estimated sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and DOR of the O-RADS system for classifying adnexal masses were 97% (95% confidence interval (CI) = 94%-98%), 77% (95% CI = 68%-84%), 4.2 (95% CI = 2.9-6.0), 0.04 (95% CI = 0.03-0.07), and 96 (95% CI = 50-185), respectively. Heterogeneity was moderate for sensitivity and high for specificity. In conclusion, the O-RADS system has good sensitivity and moderate specificity for classifying adnexal masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.